Self-assembling short immunostimulatory duplex RNAs with broad spectrum antiviral activity.
Oh, Crystal Yuri
Jordan, Tristan X
Carlson, Kenneth E
Gygi, Steven P
Jonsson, Colleen B
tenOever, Benjamin R
Ingber, Donald E
JournalMolecular Therapy Nucleic Acids
MetadataShow full item record
AbstractThe current COVID-19 pandemic highlights the need for broad-spectrum antiviral therapeutics. Here we describe a new class of self-assembling immunostimulatory short duplex RNAs that potently induce production of type I and type III interferon (IFN-I and IFN-III). These RNAs require a minimum of 20 base pairs, lack any sequence or structural characteristics of known immunostimulatory RNAs, and instead require a unique sequence motif (sense strand: 5’-C, antisense strand: 3’-GGG) that mediates end-to-end dimer self-assembly. The presence of terminal hydroxyl or monophosphate groups, blunt or overhanging ends, or terminal RNA or DNA bases did not affect their ability to induce IFN. Unlike previously described immunostimulatory siRNAs, their activity is independent of TLR7/8, but requires the RIG-I/IRF3 pathway that induces a more restricted antiviral response with a lower proinflammatory signature compared with immunostimulant poly(I:C). Immune stimulation mediated by these duplex RNAs results in broad spectrum inhibition of infections by many respiratory viruses with pandemic potential, including SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-NL63, and influenza A virus in cell lines, human Lung Chips that mimic organ-level lung pathophysiology, and a mouse SARS-CoV-2 infection model. These short dsRNAs can be manufactured easily, and thus potentially could be harnessed to produce broad-spectrum antiviral therapeutics.
Rights/Terms© 2022 The Author(s).
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19648
- Self-assembling short immunostimulatory duplex RNAs with broad spectrum antiviral activity.
- Authors: Si L, Bai H, Oh CY, Zhang T, Hong F, Jiang A, Ye Y, Jordan TX, Logue J, McGrath M, Belgur C, Nurani A, Cao W, Prantil-Baun R, Gygi SP, Powers RK, Frieman M, tenOever BR, Ingber DE
- Issue date: 2021 Nov 22
- Sequence-Specific Features of Short Double-Strand, Blunt-End RNAs Have RIG-I- and Type 1 Interferon-Dependent or -Independent Anti-Viral Effects.
- Authors: Kannan A, Suomalainen M, Volle R, Bauer M, Amsler M, Trinh HV, Vavassori S, Schmid JP, Vilhena G, Marín-González A, Perez R, Franceschini A, Mering CV, Hemmi S, Greber UF
- Issue date: 2022 Jun 28
- Effective Interferon Lambda Treatment Regimen To Control Lethal MERS-CoV Infection in Mice.
- Authors: Dijkman R, Verma AK, Selvaraj M, Ghimire R, Gad HH, Hartmann R, More S, Perlman S, Thiel V, Channappanavar R
- Issue date: 2022 Jun 8
- More tools for our toolkit: The application of HEL-299 cells and dsRNA-nanoparticles to study human coronaviruses in vitro.
- Authors: Semple SL, Alkie TN, Jenik K, Warner BM, Tailor N, Kobasa D, DeWitte-Orr SJ
- Issue date: 2022 Nov
- Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.
- Authors: Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, Baric RS
- Issue date: 2015 May 26